Flying The Web For News.
  • 2024 Presidential Election
    2024 Presidential Election
  • Career Exam Study
    Career Exam Study
  • E-commerce Guide
    E-commerce Guide
  • Dropshipping Guide
    Dropshipping Guide
  • Microsoft Exam
    Microsoft Exam
  • IT Career News
    IT Career News
+ Larger Font | - Smaller Font
Share

Globe NewsWire News Distribution Service

Press Release: Theolytics Doses First Patient in Phase I/IIa Trial of THEO-260 in Ovarian Cancer

Details
Category: Globe NewsWire News Distribution Service

Oxford, UK November 19, 2024. Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, has dosed the first patient in its Phase I/IIa multi-centre, open-label first-in-human trial (OCTOPOD - NCT06618235) of THEO-260 in patients with advanced-stage platinum-resistant ovarian cancer (PROC).


Posted: 2024-11-19 08:00:00

Get Full News Story On GlobeNewsWire Press Release Service



Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.

Tags

press | release | theolytics | doses | patient


Related News Stories From The Web And More

Related Bing News Search Results

Press Release: Theolytics Doses First Patient in Phase I/IIa Trial of THEO-260 in Ovarian Cancer - Newscast

Theolytics Doses First Patient in Phase I/IIa Trial of THEO-260 in Ovarian Cancer

Tue, 19 Nov 2024 00:26:00 GMT THEO-260 is a mechanistically novel oncolytic immunotherapy developed to tackle the stromal rich tumour microenvironment (TME) evident in ...

HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer

Wed, 30 Oct 2024 00:30:00 GMT Forward-looking statements in this press release include HOOKIPA’s statements regarding the potential of its product candidates to improve the care of the patients it seeks to treat, HOOKIPA’s ...

Nanomedicine advances deliver precise antibiotic doses to fight infections and drug resistance

Wed, 23 Oct 2024 17:00:00 GMT The two studies, "Bacteria-responsive drug release platform for the ... The aim was to develop a drug where a patient doesn't have to keep taking multiple doses to prevent reinfection.

Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor

Mon, 14 Oct 2024 00:05:00 GMT This combination is designed to meaningfully improve patient outcomes by mitigating ... Forward-Looking Statements This press release contains “forward-looking statements” within the meaning ...

Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor

Sun, 13 Oct 2024 17:00:00 GMT Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the first patient ...


Blow Us A Whistle